| Followers | 905 |
| Posts | 39660 |
| Boards Moderated | 7 |
| Alias Born | 03/22/2016 |
Tuesday, March 26, 2024 3:53:16 PM
NUVB next bio beast
Recent NUVB News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 03:25:11 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 03:23:54 PM
- Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm • PR Newswire (US) • 04/02/2026 05:19:00 PM
- Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo • PR Newswire (US) • 04/01/2026 12:00:00 PM
- Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency • PR Newswire (US) • 03/26/2026 08:05:00 PM
- Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026 • PR Newswire (US) • 03/17/2026 08:35:00 PM
- Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm • PR Newswire (US) • 03/06/2026 07:21:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 01:04:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 01:03:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 01:00:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 12:52:19 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/03/2026 09:07:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 09:22:36 PM
- Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update • PR Newswire (US) • 03/02/2026 09:05:00 PM
- Nuvation Bio to Participate in Upcoming Investor Conferences • PR Newswire (US) • 02/25/2026 09:05:00 PM
- Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026 • PR Newswire (US) • 02/17/2026 09:05:00 PM
- New Treatment Modalities Are Reaching Cancers That Resisted Everything Else • PR Newswire (Canada) • 02/17/2026 04:25:00 PM
- New Treatment Modalities Are Reaching Cancers That Resisted Everything Else • PR Newswire (US) • 02/17/2026 04:25:00 PM
- New Treatment Modalities Are Reaching Cancers That Resisted Everything Else • PR Newswire (Canada) • 02/17/2026 04:17:00 PM
- New Treatment Modalities Are Reaching Cancers That Resisted Everything Else • PR Newswire (US) • 02/17/2026 04:17:00 PM
- Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma • Business Wire • 02/09/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 01:07:18 PM
- Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference • Business Wire • 01/12/2026 01:00:00 PM
- Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan • Business Wire • 01/12/2026 12:30:00 PM
- Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference • Business Wire • 01/06/2026 09:05:00 PM
